Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent Mechanisms

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-8

  Brennan, Sarah K ^a   Wang, Qiuju ^a   Tressler, Robert ^b   Harley, Calvin ^b   Go, Ning ^b   Bassett, Ekaterina ^b   Huff, Carol Ann ^a   Jones, Richard J ^a   Matsui, William ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b GERON CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; IMETELSTAT; SYNDECAN 1; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BMI1 GENE; CELL CLONING; CELL DIFFERENTIATION; CELL GROWTH; CELL ISOLATION; CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NANOG GENE; NONHUMAN; OCT3 GENE; OCT4 GENE; PLASMA CELL; SOX2 GENE; STEM CELL; TELOMERE; ANIMAL; CANCER STEM CELL; CELL CLONE; CELL PROLIFERATION; CYTOLOGY; DOWN REGULATION; ENZYMOLOGY; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

MUS;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CLONE CELLS; DOWN-REGULATION; HUMANS; MICE; MICE, SCID; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS; TELOMERASE; TELOMERE; TUMOR CELLS, CULTURED;

EID: 77958584577     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012487     Document Type: Article

References (64)

1. Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, et al. (2009) The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 23: 2222-2232.
2. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, et al. (2004) Characterization of clonogenic multiple myeloma cells. Blood 103: 2332.
3. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, et al. (2008) Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer research 68: 190.
4. Yu GL, Bradley JD, Attardi LD, Blackburn EH (1990) In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomeraseRNAs. Nature 344: 126-132.
5. Greider CW, Blackburn EH (1985) Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43: 405-413.
6. Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. European journal of cancer (Oxford, England: 1990) 33: 787.
7. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
8. Shiratsuchi M, Muta K, Abe Y, Motomura S, Taguchi F, et al. (2002) Clinical significance of telomerase activity in multiple myeloma. Cancer genetics and cytogenetics 94: 2232.
9. Wu KD, Orme LM, Shaughnessy J, Jr., Jacobson J, Barlogie B, et al. (2003) Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 101: 4982.
10. Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, et al. (2003) Effects of oligonucleotide N39-.P59 thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer research 63: 6187.
11. Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, et al. (2008) Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia: official journal of the Leukemia Society of America, LeukemiaResearch Fund, UK 22: 1410.
12. Shammas MA, Shmookler Reis RJ, Akiyama M, Koley H, Chauhan D, et al. (2003) Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Molecular cancer therapeutics 2: 825.
13. Shammas MA, Shmookler Reis RJ, Li C, Koley H, Hurley LH, et al. (2004) Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clinical cancer research: an official journal of the American Association for Cancer Research 10: 770.
14. Wang ES, Wu K, Chin AC, Chen-Kiang S, Pongracz K, et al. (2004)Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103: 258.
15. Guo C, Geverd D, Liao R, Hamad N, Counter CM, et al. (2001) Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells. The Journal of urology 166: 694.
16. Miura N, Horikawa I, Nishimoto A, Ohmura H, Ito H, et al. (1997) Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer genetics and cytogenetics 93: 56.
17. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, et al. (2008) New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro-oncology 10: 112.
18. Kraemer K, Fuessel S, Meye A (2007) Telomerase inhibition by synthetic nucleic acids and chemosensitization in human bladder cancer cell lines. Methods in molecular biology (Clifton, NJ) 405: 9.
19. Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, Moore MA (2000) Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer research 60: 610.
20. Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, et al. (2006) Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 12: 3184.
21. Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, et al. (2005) In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer research\ 65\7866\.
22. Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, et al. (1995) Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 155: 3711-3715.
23. Harle-Bachor C, Boukamp P (1996) Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinomaderived skin keratinocytes. Proc Natl Acad Sci U S A 93: 6476-6481.
24. Yui J, Chiu CP, Lansdorp PM (1998) Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. Blood 91: 3255-3262.
25. Armanios M, Chen JL, Chang YP, Brodsky RA, Hawkins A, et al. (2005) Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A 102: 15960-15964.
26. Herbert BS, Pongracz K, Shay JW, Gryaznov SM (2002) Oligonucleotide N39-.P59 phosphoramidates as efficient telomerase inhibitors. Oncogene 21: 638-642.
27. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, et al. (1995) The RNA component of human telomerase. Science 269: 1236-1241.
28. Galderisi U, Cascino A, Giordano A (1999) Antisense oligonucleotides as therapeutic agents. J Cell Physiol 181: 251-257.
29. Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Wan X, et al. (1998) Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res 58: 5406-5410.
30. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO (1999) Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 13: 2388-2399.
31. Strahl C, Blackburn EH (1996) Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 16: 53-65.
32. Brower V, Telomerase-based therapies emerging slowly. J Natl Cancer Inst 102: 520-521.
33. Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 16: 154-163.
34. Shay JW (1997) Telomerase in human development and cancer. Journal of cellular physiology 173: 266.
35. Baird DM, Rowson J, Wynford-Thomas D, Kipling D (2003) Extensive allelic variation and ultrashort telomeres in senescent human cells. Nat Genet 33: 203-207.
36. Choi J, Southworth LK, Sarin KY, Venteicher AS, Ma W, et al. (2008) TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS genetics 4: e10.
37. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, et al. (2009) Human induced pluripotent stem cells free of vector and transgene sequences. Science 324: 797-801.
38. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.
39. Ebert AD, Yu J, Rose FF, Jr., Mattis VB, Lorson CL, et al. (2009) Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457: 277-280.
40. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, et al. (2007) Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12: 528-541.
41. Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, et al. (2007) Frequent and specific immunity to the embryonal stem cell-associated antigenSOX2 in patients with monoclonal gammopathy. J Exp Med 204: 831-840.
42. Duncan AW, Rattis FM, DiMascio LN, Congdon KL, Pazianos G, et al. (2005) Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 6: 314-322.
43. Lessard J, Sauvageau G (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255-260.
44. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
45. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, et al. (2003) Telomerase maintains telomere structure in normal human cells. Cell 114:241-253.
46. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW (1996) Telomerase activity in human germline and embryonic tissues and cells. Developmental genetics 18: 173.
47. Flores I, Canela A, Vera E, Tejera A, Cotsarelis G, et al. (2008) The longest telomeres: a general signature of adult stem cell compartments. Genes & development 22: 654.
48. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, et al. (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955-959.
49. Vulliamy T, Marrone A, Dokal I, Mason PJ (2002) Association between aplastic anaemia and mutations in telomerase RNA. Lancet 359: 2168-2170.
50. Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, et al. (2005) Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 352: 1413-1424.
51. Yuan X, Ishibashi S, Hatakeyama S, Saito M, Nakayama J, et al. (1999) Presence of telomeric G-strand tails in the telomerase catalytic subunit TERT knockout mice. Genes Cells 4: 563-572.
52. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, et al. (1997) Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91: 25-34.
53. Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, et al. (2003) Effects of oligonucleotide N39-.P59 thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res 63: 6187-6194.
54. Jackson SR, Zhu CH, Paulson V, Watkins L, Dikmen ZG, et al. (2007) Antiadhesive effects of GRN163L-an oligonucleotide N39-.P59 thio-phosphoramidate targeting telomerase. Cancer research 67: 1121.
55. Rossi A, Russo G, Puca A, La Montagna R, Caputo M, et al. (2009) The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells. Int J Cancer 125: 235-243.
56. Bagheri S, Nosrati M, Li S, Fong S, Torabian S, et al. (2006) Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl AcadSci U S A 103: 11306-11311.
57. Hao LY, Armanios M, Strong MA, Karim B, Feldser DM, et al. (2005) Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 123: 1121-1131.
58. Sarin KY, Cheung P, Gilison D, Lee E, Tennen RI, et al. (2005) Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436: 1048.
59. Li S, Crothers J, Haqq CM, Blackburn EH (2005) Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J Biol Chem 280: 23709-23717.
60. Samper E, Fernandez P, Eguia R, Martin-Rivera L, Bernad A, et al. (2002) Long-term repopulating ability of telomerase-deficient murine hematopoietic stem cells. Blood 99: 2767-2775.
61. Allsopp RC, Morin GB, DePinho R, Harley CB, Weissman IL (2003) Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood 102: 517-520.
62. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, et al. (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105: 4163-4169.
63. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, et al. (2009) Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460: 66-72.
64. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, et al. (2005) International staging system for multiple myeloma. J Clin Oncol 23: 3412-3420.